Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemons ...

In the rapidly evolving landscape of global pharmaceuticals, China has emerged as a formidable player, transitioning from a dominant producer of generic drugs to a hub for innovative medicines. Over ...

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will present its latest breakthroughs in AI-driven facial and ...

Signature Resolution, a leader in alternative dispute resolution, is proud to announce that Andrew E. Westley has joined the firm as a mediator. Over the course of his 40-year career as a litigator ...

Pfizer ( PFE) is set to report its Q3 earnings on Tuesday, November 4, before the market opens. Wall Street expects earnings ...

Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

Pfizer offers an annual dividend yield of 6.98%, or $1.72 a year. Here's how investors can pocket a regular $500 monthly.

Better still, if interest rates drop, as they're generally expected to over the coming year, the interest income you'll get ...

The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around ...

Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol ...

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...